Inxilon

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Inxilon

What is Inxilon? (Quick Overview)

To provide a clear, immediate definition of this medicine, here are the key facts about its identity and nature:

Property Description
Active ingredient Methylprednisolone
Form Oral tablet and injectable solutions
Pharmacological class Synthetic Glucocorticoid (Corticosteroid)
Common use Reducing severe inflammation and immune response
Origin Synthetic (Man-made)

What is Inxilon and What Kind of Medicine Is It?

Inxilon is the brand name for a medication whose active ingredient is the potent drug methylprednisolone, which is classified as a synthetic corticosteroid. This drug belongs to the class of glucocorticoids, which are modeled after the natural hormone cortisol, produced by the adrenal glands. Pharmacological studies have long established the efficacy of methylprednisolone in rapidly controlling various systemic inflammatory processes.

Identity: Forms and Composition

Inxilon is a single-ingredient medicine available most commonly as an oral tablet and in various sterile solutions for injection (parenteral use). Glucocorticoids, both naturally occurring and synthetic like methylprednisolone, are readily absorbed from the body's systems. Because it is a single-ingredient medicine, it delivers a focused therapeutic agent. The availability of multiple dosage forms provides flexibility in administering the drug depending on the patient's specific needs.


What Is Inxilon’s General Purpose?

Inxilon’s primary general purpose is to powerfully reduce inflammation and modulate the activity of the immune system. By mimicking the effects of the natural stress hormone, the drug blocks the complex signals that trigger and sustain the body's inflammatory and immune responses. This action is critical for controlling swelling, redness, pain, and other symptoms associated with various inflammatory and autoimmune disorders, helping to stabilize the underlying condition by quieting the body's overactive defense mechanisms.

Regulatory References

  1. Methylprednisolone

What side effects are possible with Inxilon?

Possible Side Effects and Safety Information for Inxilon

Inxilon, which contains methylprednisolone, is a powerful corticosteroid and is associated with a range of dose- and duration-dependent adverse reactions. Its safety profile is largely consistent with the systemic use of glucocorticoids, characterized primarily by immunosuppression and metabolic/endocrine effects.

Key adverse reactions, classified by system-organ class, include:

  • Infections and Infestations: Increased susceptibility to new infections (bacterial, viral, fungal, or parasitic) and masking of infection symptoms. The drug is contraindicated in patients with systemic fungal infections.
  • Endocrine and Metabolic: Adrenal suppression, particularly following prolonged use or abrupt withdrawal, which can be severe. Other common effects include fluid retention, alterations in glucose tolerance (which may require adjustment of diabetes medication), and the development of a Cushingoid state.
  • Musculoskeletal and Ophthalmic: Long-term or high-dose therapy can lead to a decrease in bone density (osteoporosis), muscle weakness (myopathy), and damage to the optic nerve, including cataracts and glaucoma.

Serious and Clinically Significant Risks

Serious adverse reactions documented in regulatory sources include adrenal insufficiency (upon abrupt cessation after chronic use), severe infections, gastrointestinal perforation and bleeding (especially in patients with pre-existing GI disorders), and severe psychiatric disturbances (e.g., mood swings, psychosis).

Safety Monitoring and Restrictions

Monitoring is necessary for blood pressure, serum electrolytes, and signs of infection. Due to its immunosuppressive action, live or live-attenuated vaccines are generally restricted during treatment with Inxilon. Caution is specifically advised in populations with pre-existing conditions such as hypertension, diabetes mellitus, heart failure, osteoporosis, and active or latent peptic ulcer.

Overdose and Emergency Response

Overdose and When to Seek Urgent Help for Inxilon

While official regulatory labeling for Inxilon may not define a precise dose-related acute overdose profile, it is critical to recognize that taking any medication in excess can lead to serious adverse health consequences. Overdose information generally describes symptoms across various body systems, often resulting from excessively high drug exposure.

Overdose presentations from systemic exposure to similar medications may include a disturbance in fluid and electrolyte balance, which can manifest as swelling, unusual weakness, or heart rhythm changes. Other severe manifestations can potentially affect the nervous system, such as seizures or changes in mental state, or may worsen existing health conditions like heart failure or diabetes.

Overdose scope (Authoritative Sources) Description
Documented Presentations Symptoms can involve fluid/electrolyte imbalance, nervous system changes, and acute metabolic disturbances.
Physiological Systems Cardiovascular, metabolic, nervous, and musculoskeletal systems are primary areas of concern.
Emergency Action Urgent medical attention is required. Immediate contact with poison control or emergency services is mandatory.

When Immediate Medical Help is Required

Seek immediate emergency medical help by calling the Poison Control Center or emergency services if you suspect an overdose or experience severe, sudden symptoms after taking this medication. Do not wait for symptoms to worsen. Providing emergency personnel with details about the substance and the amount taken is crucial for proper medical management.

Therapeutic Uses of Inxilon

Inxilon (methylprednisolone) is commonly used in clinical settings to manage severe, episodic symptoms across multiple therapeutic domains, supporting relief in situations involving heightened physiological activity. It is applied when appropriate in situations where acute manifestations disrupt functional stability and require short-term supportive management.

This medication is relevant in conditions characterized by periods of heightened symptoms and is commonly used for managing conditions such as severe allergic reactions, rheumatoid arthritis flares, Systemic Lupus Erythematosus, acute asthma exacerbations, and inflammatory bowel diseases like ulcerative colitis.

It helps address symptoms that create noticeable physiological strain, such as those related to physical discomfort and functional stress. The relevant benefit is offering symptomatic relief that helps patients cope more steadily with difficult episodes, supporting general well-being during symptomatic phases.

“Inxilon is primarily relevant for easing symptoms that become more disruptive during flare-ups of chronic conditions.”

The medication is often used during phases when symptoms become more noticeable and may assist with maintaining functional stability.


Relevant Use: Symptomatic Support for Inflammatory States

Inxilon is applied across domains where additional symptomatic support is needed to address symptom clusters related to inflammatory or irritative states, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. Methylprednisolone Injection: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Inxilon?

The eligibility criteria for Inxilon (methylprednisolone) are strictly defined by official regulatory bodies, identifying populations for whom use is prohibited (contraindicated) and those requiring special caution.


Populations Prohibited from Using Inxilon

The medicine is absolutely contraindicated in patients with a systemic fungal infection or a known hypersensitivity to methylprednisolone or any of the product's components. Furthermore, certain formulations containing benzyl alcohol are prohibited for use in neonates and premature infants. Specific administration routes, such as intrathecal or epidural injection, are also prohibited for all patients.


Eligibility Conditions and Restrictions

Population/Condition Restriction / Precaution
Age Groups Pediatric growth must be monitored; geriatric patients require close supervision.
Pregnancy/Lactation Use is conditional; benefits must outweigh potential risks to the fetus or infant.
Comorbidities Caution is advised for patients with latent tuberculosis or a recent myocardial infarction.

Inxilon is generally approved for use in both adult and pediatric populations for its established indications, provided no contraindications exist.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Inxilon are mainly structured around the drug's metabolism and its effects when combined with other medicinal products. The primary mechanism for drug-drug interactions involves the Cytochrome P450 3A4 (CYP3A4) enzyme, which is responsible for the product's clearance.

Interacting Class/Category Official Interaction Statement Constraint / Requirement
CYP3A4 Inhibitors (e.g., ketoconazole) May significantly decrease the clearance of Inxilon, increasing its blood concentrations and effects. Close monitoring for increased effects of Inxilon is required.
CYP3A4 Inducers (e.g., rifampin, phenytoin) May significantly increase the clearance of Inxilon, decreasing its blood concentrations and potentially reducing its effectiveness. Monitoring for decreased effectiveness of Inxilon is required.
Anticoagulant Agents (e.g., warfarin) May either enhance or diminish the anticoagulant effects. Coagulation indices must be monitored closely to ensure proper anticoagulant effect.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Concomitant use increases the risk of gastrointestinal ulceration and hemorrhage. Use together should be approached with caution due to additive GI toxicity risk.
Anticholinesterase Agents May result in severe muscle weakness in patients with myasthenia gravis. These agents should be withdrawn at least 24 hours prior to initiating Inxilon therapy.

Official documentation also notes that Inxilon may increase blood glucose levels, which may require dose adjustments for antidiabetic agents used concurrently. Furthermore, the co-administration of Inxilon with Potassium-Depleting Agents (e.g., diuretics) may enhance potassium loss, necessitating the monitoring of serum potassium levels. Live or live attenuated vaccines should generally not be administered to patients receiving immunosuppressive doses of this product.

Mechanism of Action

Inxilon (Methylprednisolone) initiates activity via a detailed pharmacodynamic mechanism centered on two primary domains of action at the cellular level.

Glucocorticoid Receptor Agonism and Gene Control

Inxilon acts as a high-affinity agonist for the intracellular Glucocorticoid Receptor ( GR), initiating a genomic cascade. This receptor complex enters the cell nucleus to perform transrepression, which is the mechanism of inhibiting pro-inflammatory genes ( NF-kappa B and AP-1), and transactivation, which is the upregulation of anti-inflammatory protein synthesis.

Suppression of Inflammatory Mediators and Immune Cells

The genomic action directly results in the suppression of the Arachidonic Acid Cascade by inducing proteins like lipocortin-1 ( ANXA1), which blocks PLA2 activity, thereby preventing the synthesis of prostaglandins and leukotrienes. This cascade interference, coupled with the systemic reduction in the activity and migration of key immune cells (lymphocytes, monocytes), diminishes inflammatory signals, establishing the drug's anti-inflammatory and immunosuppressive physiological profile.

Mechanistic Limitations

The drug’s core mechanism, dependent on genomic signaling (gene transcription and protein turnover), exhibits a time lag, resulting in the establishment of the maximal physiological consequence over hours or days. Furthermore, certain biological states, like glucocorticoid resistance, can functionally limit the mechanism's intrinsic activity.

Dosage and Administration Information

How to Use Inxilon (Methylprednisolone) — Official Administration Guidelines

Inxilon, containing the corticosteroid methylprednisolone, is administered via multiple routes based on the specific condition. The administration must strictly follow the method and dose determined by a healthcare provider.


Official Routes and Forms

Administration Route Labeled Dosage Form Procedural Constraints
Oral Tablet (e.g., 4 mg, 8 mg) May be taken with food or milk to reduce stomach upset.
Intravenous (IV) Powder for Injection (Sodium Succinate) Doses over 250 mg must be administered over a period of at least 30 minutes.
Intramuscular (IM) Injectable Suspension (Acetate) or Sodium Succinate Injection into the deltoid muscle should be avoided when using the suspension form.
Local Injection Injectable Suspension (Acetate) Used for intra-articular, intralesional, and soft tissue injections.

Dosing and Scheduling Protocol

The dosage of methylprednisolone is highly individualized; there is no single standard dose. The initial dose ranges widely and is determined by the patient's condition.

Gradual Reduction (Tapering): For patients receiving long-term treatment, the dose must be gradually reduced rather than abruptly stopped. This process of tapering is essential to find the lowest effective maintenance dose or safely discontinue the drug. Alternative schedules, such as Alternate Day Therapy (ADT), may be prescribed for long-term use.

Preparation and Restrictions

Injectable powder formulations require reconstitution with the provided or specified diluent before administration. The specific official instructions contraindicate the use of the drug via certain routes, such as the intrathecal (into the spinal fluid) or epidural routes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Inxilon

Evidence for Use in Metastatic Colorectal Carcinoma

Research has studied Inxilon primarily through a large Phase III Randomized Controlled Trial (RCT) conducted in adult patients. These studies were applied in research contexts involving patients whose metastatic colorectal carcinoma had progressed despite receiving prior standard treatments. Research explored study endpoints related to overall survival and measured patient-reported outcomes capturing perceived discomfort and systemic imbalance.

The studies reported that the main Phase III trial was terminated early. This is a factor in the amount of data available regarding overall survival. Findings described patterns observed in the studies regarding the comparison between the group receiving Inxilon and the group receiving a placebo (an inactive substance). Data show patterns related to changes measured during the study period for physical discomfort and daily functioning or activity level. These findings describe group patterns, not personal outcomes.

Understanding Long-Term Studies and Follow-up

Research has explored study endpoints over defined time intervals, but long-term data on these endpoints are not well characterized. There is limited information for long-term outcomes regarding the patterns of overall survival or sustained change in symptoms beyond the intermediate follow-up periods of the conducted trials. Data regarding sustained patterns of change for Inxilon are still emerging. Findings describe group patterns, not personal outcomes, and the follow-up durations were limited in the main study.

What is Still Uncertain About Inxilon Research

Many aspects of the research for Inxilon remain uncertain. The early termination of the main Phase III trial is a factor in the amount of data available regarding overall survival. Evidence quality varies across studies, and the initial sample sizes were modest in some of the smaller research settings. The research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain.

Key Studies & References

  1. Phase 3 Trial of MABp1 (Xilonix) in Refractory Colorectal Cancer (NCT01767857)
  2. Systematic Review of Phase III Trials for Refractory Metastatic Colorectal Cancer
  3. ICH Harmonised Guideline: General Considerations for Clinical Trials (E8 R1)

Frequently Asked Questions (FAQ)

Common questions about Inxilon (FAQ)

Q: How quickly does Inxilon start to work after starting treatment?

A: According to official prescribing information, Inxilon works by affecting the body’s inflammatory response at the cellular level. Because this involves changes in gene activity, the full effect on the body's processes may become noticeable over a period of hours or days, rather than immediately.

Q: Does Inxilon cause weight gain or weight loss?

A: Regulatory documents state that weight gain and an increase in appetite are frequently reported side effects. This is often associated with the fluid retention and metabolic changes that can occur when taking corticosteroids.

Q: Can I take Inxilon if I have an existing heart condition?

A: Official labeling advises that caution is necessary for patients with pre-existing conditions like hypertension (high blood pressure) or congestive heart failure. This is because corticosteroids can promote fluid retention and potentially raise blood pressure.

Q: Are there any long-term effects of taking Inxilon for several years?

A: Official product information notes that long-term use is associated with a range of dose- and duration-dependent effects. These effects can include a decrease in bone density (osteoporosis), changes in vision such as the development of cataracts or glaucoma, and potential suppression of the adrenal glands.

Q: What are the most common side effects reported for Inxilon?

A: According to official regulatory sources, commonly reported side effects may include fluid retention, changes in glucose tolerance, increased blood pressure, increased appetite, and mood or behavioral changes. The severity and type of side effects can vary depending on the dose and how long the drug is used.

Q: Is Inxilon safe to use during pregnancy or while breastfeeding?

A: Regulatory documents specify that use during this time is conditional, meaning the potential benefits must be weighed against any potential risk to the fetus or infant. Caution is specifically advised regarding formulations containing benzyl alcohol.

Q: Do I need to avoid any specific foods or drinks while on Inxilon?

A: Official patient guides and interaction data indicate that consumption of grapefruit and grapefruit juice may interact with Inxilon and could increase the risk of side effects. Oral forms of the medicine may be taken with food or milk to help reduce stomach upset.

Q: Is Inxilon treatment a permanent thing, or can I stop it later?

A: Inxilon is often used for short periods to manage acute conditions. If the drug is used long-term, official instructions require that the dose be gradually reduced (tapered) rather than stopped abruptly, as sudden cessation may cause severe effects.

Q: What are the clinical trial results that led to Inxilon’s approval?

A: The drug’s approval is based on a body of clinical evidence demonstrating its consistent effectiveness as a potent anti-inflammatory and immunosuppressive agent for its established range of indications. Detailed findings are available in the official prescribing information documents.

Q: Does Inxilon interact with herbal supplements like St. John's Wort?

A: Official documentation advises caution, as the drug is broken down by the CYP3A4 enzyme. Herbal supplements that interfere with this enzyme (such as St. John’s Wort) may affect the concentration of Inxilon. Combined use with some herbal supplements may affect drug levels.

Q: What are the signs of a serious or rare side effect from Inxilon?

A: Serious symptoms documented in regulatory sources include signs of severe infection (fever, chills, sore throat), bloody or black stools (G.I. bleeding), unusual weakness, and severe changes in mood or behavior. If you experience any unexpected or severe reaction, seek attention from a healthcare provider.

Q: How is Inxilon different from other classes of drugs for the same condition?

A: Inxilon is classified as a corticosteroid (glucocorticoid class). It differs from non-steroidal drugs by acting as a powerful hormone mimic that directly suppresses the immune system and broadly blocks inflammatory signals at the genetic level.

Q: Is it true that Inxilon is still being studied?

A: Studies on Inxilon continue, as research has investigated its use for complications related to severe inflammatory conditions, including new respiratory illnesses. Additionally, data regarding long-term outcomes and sustained changes are still emerging.

Q: Is there a chance that Inxilon will suddenly stop working for me?

A: Official warnings mention that in rare instances, the drug's mechanism can be limited by a biological state known as glucocorticoid resistance. Monitoring by a healthcare provider may be required to check if the treatment remains effective.

Q: Is Inxilon considered a high-risk medication?

A: As a potent corticosteroid, the drug is associated with a range of serious and clinically significant risks documented in official labeling, including severe infections, adrenal gland suppression, and psychiatric disturbances. Due to its risk profile, use typically requires close monitoring by a healthcare professional.

Q: What research is currently underway for new uses of Inxilon?

A: Clinical trials are generally ongoing to investigate the drug’s potential utility in managing specific symptoms and complications associated with severe inflammatory conditions across various medical specialties. Information about specific current trials is available from public registries.

Q: Is it normal to feel tired or fatigued when first starting Inxilon?

A: Official regulatory documents list fatigue and unusual tiredness or weakness as possible undesirable effects of treatment. Any persistent or severe fatigue is a symptom that may warrant attention from a healthcare provider.

Q: What is the official definition of Inxilon's safety classification?

A: Inxilon is officially classified as a Synthetic Glucocorticoid (Corticosteroid). The detailed description of its safety profile, including all warnings, precautions, and adverse reactions, is contained within the official labeling.

Q: Does Inxilon affect my ability to drive or operate machinery?

A: Official documentation states that the drug can cause undesirable effects such as dizziness, vertigo, visual disturbances, and fatigue. If these effects occur, official guidance states that operating machinery or driving may be affected.

Q: Is there a generic version of Inxilon available?

A: Yes, the active ingredient in Inxilon is methylprednisolone. The FDA and DailyMed records confirm that methylprednisolone is available in multiple generic oral and injectable formulations.

Q: What happens if I accidentally miss a dose of Inxilon?

A: For patients on a once-daily morning dose, standard patient instructions suggest that if a dose is missed, it should generally be taken that same day once remembered. However, if a full day has passed, the missed dose is typically skipped, and the regular schedule is resumed. Always confirm specific instructions.

Q: Why do some patients feel worse when they first start Inxilon?

A: Clinical experience described in regulatory documents shows that the onset of side effects can be rapid. Certain central nervous system effects, such as mood changes, and gastrointestinal symptoms can appear shortly after starting treatment. Any worsening of symptoms or development of new effects is a clinical finding that should be reviewed.

Q: Is Inxilon covered by most insurance plans?

A: As a logistical matter, coverage and cost vary significantly based on individual insurance plans and their specific drug formulary. Some plans may require prior authorization for coverage before the cost is covered.

Q: Is Inxilon safe to take with birth control pills?

A: Regulatory documents on drug-drug interactions state that oral contraceptives containing estrogen may significantly increase the blood levels of methylprednisolone. This elevated level could potentially increase the risk or severity of side effects.

Q: Does alcohol consumption affect the safety or effectiveness of Inxilon?

A: Official patient guides caution against alcohol use during treatment. Combining alcohol with this medication may worsen certain side effects and can increase the risk of serious complications, such as gastrointestinal bleeding and bone loss.

Q: Does the time of day matter when taking Inxilon?

A: For patients on a once-daily dosing schedule, it is often recommended to take the tablet in the morning. This clinical practice is based on the goal of aligning the medication with and mimicking the body's natural cycle of stress hormone production.

Q: Can Inxilon cause problems with the liver or kidneys?

A: Official labeling notes that the drug is associated with a risk of reversible elevations in liver enzymes ( AST, ALT). While it is sometimes used to treat various kidney diseases, careful monitoring is necessary, particularly when combined with other specific medications.

Q: Why is Inxilon prescribed as a last resort in some cases?

A: Its use is typically reserved for serious conditions due to its potent immunosuppressive action and the risk of severe and systemic side effects detailed in official warnings. This risk profile often dictates its use in circumstances where the clinical benefits clearly outweigh the risks.

Q: Is Inxilon safe for someone with a history of cancer?

A: Corticosteroids like Inxilon have an established role in cancer treatment, used for managing side effects like chemotherapy-related nausea, swelling, and fatigue. Any use must be closely supervised by a healthcare provider familiar with the patient's history.

Q: How does Inxilon compare in cost to its alternatives?

A: Logistical information indicates that the cost of the readily available generic form (methylprednisolone) is generally lower than some alternative specialty biologics used for similar conditions. Actual patient costs are highly dependent on insurance coverage and pharmacy pricing.

Q: Is Inxilon a painkiller?

A: Inxilon is classified as a potent anti-inflammatory and immunosuppressive agent. While it can reduce pain by significantly decreasing inflammation, it is not classified as a simple analgesic or 'painkiller' drug.

Q: Does Inxilon affect fertility in men or women?

A: Clinical data regarding its use in contexts like IVF treatment suggests that it may not significantly affect the chances of pregnancy. However, its potential to affect hormone levels and immune cells means this is a topic that may require review with a specialist.

How should Inxilon be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documents define precise conditions for storing and disposing of this medication (methylprednisolone) to maintain its quality and ensure safety.

Requirement Area Official Regulatory Mandate
Storage Temperature Must be stored at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), protected from excess heat and moisture.
Light/Container Protection The product must be kept in its original, tightly closed container and shielded from light. It must also be kept from freezing.
Stability After Mixing The injectable solution, once reconstituted, must be used within 48 hours when stored at Controlled Room Temperature.
Child Safety The medication must be kept out of the sight and reach of children in a secured location.
Disposal Instructions Unused or expired doses should be discarded using an authorized drug take-back program. Sharps (needles/syringes) must be placed in an FDA-cleared sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Inxilon found in:

A-Z Index: